Phase II Study of Carboplatin and Bevacizumab (Avastin) for ER Neg, PR Neg, and HER2/Neu Neg Metastatic Breast Cancer

Metastatic Breast Cancer Clinical Trial

Official title:

A Phase II Study of Carboplatin and Bevacizumab (Avastin) Combination Therapy for ER Negative, PR Negative, and HER2/Neu Negative Metastatic Breast Cancer

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00517361
• Other study ID #: 15578A
• Status: Terminated
• Phase: Phase 2
• First received: August 14, 2007
• Last updated: March 10, 2014
• Start date: August 2007
• Est. completion date: April 2012

Study information

• Verified date: March 2014
• Source: University of Chicago
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine the progression free survival (PFS) of metastatic ER, PR and HER2/neu negative breast cancers to the combination of carboplatin and bevacizumab (Avastin®) therapy.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 11
• Est. completion date: April 2012
• Est. primary completion date: April 2011
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients must have pathologically confirmed ER, PR and HER2/neu negative (FISH ratio of <2.0 or IHC <1+) metastatic breast cancer. Locally advanced or recurrent disease is also eligible.

• Patients must have measurable disease

• Patients must not have received prior chemotherapy for metastatic breast cancer (not including adjuvant therapy). Patients should be > 4 weeks from their most recent chemotherapy or radiation therapy treatment.

• Age >18 years

• ECOG performance status <1 (Karnofsky >80%).

• Patients must have normal organ and marrow function as defined below:

• absolute neutrophil count >1,500/uL

• platelets >100,000/uL

• total bilirubin within normal institutional limits

• AST(SGOT)/ALT(SGPT) <2.5X institutional upper limit of normal

• creatinine within normal institutional limits OR creatinine clearance>60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal

• PT INR < 1.5 (Unless patient is on anticoagulation)

• urine protein <1+

• Tissue from the primary tumor must be available for correlative studies

• Women of child-bearing potential must agree to use adequate contraception

• Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

• Patients who have had prior therapy with platinum agents or a VEGF inhibitor are not eligible.

• Patients may not be receiving any other investigational agents.

• Patients with known brain metastases will be excluded

• Patients may have had prior radiation therapy, provided the patient has measurable disease and there has been clear progression since the completion of radiation therapy. Patients who have had radiotherapy within 4 weeks prior to entering the study or those who have not recovered from adverse events due to therapy administered more than 4 weeks earlier will be excluded.

• Patients with significant cardiac dysfunction will be excluded

• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.

• Pregnant women are excluded from this study, breastfeeding should be discontinued.

• HIV-positive patients receiving combination anti-retroviral therapy are excluded from the study because of possible pharmacokinetic interactions with carboplatin or the other agents administered during the study.

• Patients with evidence of bleeding diathesis or coagulopathy.

• Patients with inadequately controlled hypertension will be excluded

• Patients who have had a stroke or TIA within 6 months of registration will be excluded.

• Patients with a history of hypertensive crisis or hypertensive encephalopathy will be excluded.

• Patients with a history of abdominal fistula, GI perforation, or intra-abdominal abscess within 6 months of registration.

• Patient with history of serious non-healing wound, ulcer or bone fracture.

• Patients with major surgery, open biopsy, or significant traumatic injury within 28 days of registration or anticipated need for surgery during course of study treatment.

• Patients with a history core biopsy or other minor surgery, excluding venous access device (VAD) placement, within 7 days of registration.

• Patients with active second malignancy.

• Known hypersensitivity to any component of bevacizumab (Avastin®).

• Peripheral neuropathy > Grade 1.

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Breast Neoplasms
• Metastatic Breast Cancer

Intervention

Drug:
• carboplatin
AUC 6 in 250mL saline IV over 30 minutes
• bevacizumab
15mg/kg in 100mL saline IV over 60 - 90 minutes

Locations

Country	Name	City	State
United States	University of Chicago	Chicago	Illinois
United States	Oncology Specialists	Park Ridge	Illinois

Sponsors (2)

Lead Sponsor	Collaborator
University of Chicago	Genentech, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progression Free Survival	Progression is defined using the international criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST) Committee [JNCI 92(3):205-216, 2000], as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since the treatment started or the appearance of one or more new lesions, or appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions.	Up to 5 years	No
Secondary	Response Rate	Response is defined using the international criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST) Committee [JNCI 92(3):205-216, 2000]: Complete Response (CR), Disappearance of all target lesions or disappearance of all non-target lesions and normalization of tumor marker level; Partial Response (PR), At least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD; Stable Disease (SD), Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum LD since the treatment started, or persistence of one or more non-target lesion(s) and/or maintenance of tumor marker level above the normal limits.	Up to 5 years	No
Secondary	Duration of Response		Up to 5 years	No
Secondary	Correlation of Response to BRCA1 Methylation Status	The methylation status of the tumor is defined using Methylation Specific polymerase chain reaction and/or pyrosequencing.	Up to 5 years	No